These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29217526)

  • 1. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.
    Hidalgo M; Martinez-Garcia M; Le Tourneau C; Massard C; Garralda E; Boni V; Taus A; Albanell J; Sablin MP; Alt M; Bahleda R; Varga A; Boetsch C; Franjkovic I; Heil F; Lahr A; Lechner K; Morel A; Nayak T; Rossomanno S; Smart K; Stubenrauch K; Krieter O
    Clin Cancer Res; 2018 Apr; 24(7):1536-1545. PubMed ID: 29217526
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
    Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
    Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
    Herbst RS; Hong D; Chap L; Kurzrock R; Jackson E; Silverman JM; Rasmussen E; Sun YN; Zhong D; Hwang YC; Evelhoch JL; Oliner JD; Le N; Rosen LS
    J Clin Oncol; 2009 Jul; 27(21):3557-65. PubMed ID: 19546406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
    Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
    Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
    Spratlin JL; Cohen RB; Eadens M; Gore L; Camidge DR; Diab S; Leong S; O'Bryant C; Chow LQ; Serkova NJ; Meropol NJ; Lewis NL; Chiorean EG; Fox F; Youssoufian H; Rowinsky EK; Eckhardt SG
    J Clin Oncol; 2010 Feb; 28(5):780-7. PubMed ID: 20048182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
    Mueller T; Freystein J; Lucas H; Schmoll HJ
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
    Jimeno A; Moore KN; Gordon M; Chugh R; Diamond JR; Aljumaily R; Mendelson D; Kapoun AM; Xu L; Stagg R; Smith DC
    Invest New Drugs; 2019 Jun; 37(3):461-472. PubMed ID: 30229512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.
    Goff LW; Cohen RB; Berlin JD; de Braud FG; Lyshchik A; Noberasco C; Bertolini F; Carpentieri M; Stampino CG; Abbattista A; Wang E; Borghaei H
    Clin Cancer Res; 2016 May; 22(9):2146-54. PubMed ID: 26655846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.
    Yamamoto N; Koyama T; Shimizu T; Todaka A; Kawakami T; Erzen D; Sarashina A; Li B; Hou J; Yamazaki K
    Cancer Chemother Pharmacol; 2023 Jun; 91(6):469-480. PubMed ID: 37140602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
    Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C
    J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.
    Dowlati A; Vlahovic G; Natale RB; Rasmussen E; Singh I; Hwang YC; Rossi J; Bass MB; Friberg G; Pickett CA
    Clin Cancer Res; 2016 Sep; 22(18):4574-84. PubMed ID: 27076631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
    Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
    Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.
    Massard C; Soria JC; Krauss J; Gordon M; Lockhart AC; Rasmussen E; Upreti VV; Patel S; Ngarmchamnanrith G; Henary H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1057-1063. PubMed ID: 30915497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.
    Gordon MS; Robert F; Matei D; Mendelson DS; Goldman JW; Chiorean EG; Strother RM; Seon BK; Figg WD; Peer CJ; Alvarez D; Adams BJ; Theuer CP; Rosen LS
    Clin Cancer Res; 2014 Dec; 20(23):5918-26. PubMed ID: 25261556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies.
    Heil F; Babitzki G; Julien-Laferriere A; Ooi CH; Hidalgo M; Massard C; Martinez-Garcia M; Le Tourneau C; Kockx M; Gerber P; Rossomanno S; Krieter O; Lahr A; Wild N; Harring SV; Lechner K
    Transl Oncol; 2021 Feb; 14(2):100984. PubMed ID: 33338877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
    Guibal A; Taillade L; Mulé S; Comperat E; Badachi Y; Golmard JL; Le Guillou-Buffello D; Rixe O; Bridal SL; Lucidarme O
    Radiology; 2010 Feb; 254(2):420-9. PubMed ID: 20093514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.
    Papadopoulos KP; Gluck L; Martin LP; Olszanski AJ; Tolcher AW; Ngarmchamnanrith G; Rasmussen E; Amore BM; Nagorsen D; Hill JS; Stephenson J
    Clin Cancer Res; 2017 Oct; 23(19):5703-5710. PubMed ID: 28655795
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.